Novotech

Novotech Earns Great Place to Work® Certification in the United States

BOSTON – Novotech, a global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been certified as a Great Place to Work® in the United States. This award reflects Novotech’s commitment to fostering a flexible, inclusive, and innovative work environment where employees feel supported and empowered to contribute to the future of medical research. “Our employees are the heart of Novotech, … Continue reading Novotech Earns Great Place to Work® Certification in the United States

Radar Therapeutics

Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular RNA Sensors

BERKELEY, Calif. – Radar Therapeutics, a biotech company developing smart programmable medicines, today announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC and other investors. The financing will support advancement of Radar’s internal programs, team expansion and partnering. “Like … Continue reading Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular RNA Sensors

Scenic Biotech

Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

Bristol Myers Squibb gains access to Scenic’s Cell-Seq technology platform to unlock the underlying genetic interactions of cellular pathways for undisclosed targets Scenic to receive an upfront payment and potential additional payments contingent on the achievement of research, development and commercial milestones AMSTERDAM – Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into … Continue reading Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

Domain Therapeutics

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

February 27, 2024 07:10 AM Eastern Standard Time STRASBOURG, France & MONTREAL & BOSTON–(BUSINESS WIRE)–Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO). Stephan will oversee the development of Domain’s proprietary … Continue reading Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Domain Therapeutics

Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

STRASBOURG, France & MONTREAL & BOSTON–(BUSINESS WIRE)–Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team. In his new position, Sean will lead corporate strategy and business development bringing broad and deep … Continue reading Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

Intelecy

Industrial AI Company Intelecy Appoints Camilla Gjetvik as New CEO

Gjetvik is a seasoned AI executive and a proven company builder, making her an ideal fit for Intelecy’s vision of using AI to enable more sustainable industrial production. OSLO, Norway–(BUSINESS WIRE)–Intelecy is a pioneer in no-code AI applications for optimizing industrial processes to reduce waste, emissions, energy consumption, and costs. The company is now strengthening its leadership team with a new CEO. Camilla Gjetvik brings … Continue reading Industrial AI Company Intelecy Appoints Camilla Gjetvik as New CEO

Alentis Therapeutics

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

Velji brings more than 20 years of experience in biotech financial services December 06, 2023 08:00 AM Eastern Standard Time BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointed Chief Business Officer (CBO). He will lead corporate strategy, business development, and finance. Rizwan Velji, Chief Business Officer … Continue reading Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

MYTOS

Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth

November 30, 2023 08:00 AM Eastern Standard Time LONDON–(BUSINESS WIRE)–Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC. “Mytos is revolutionizing cell manufacturing, providing a simple solution that pharma and biotech companies can easily integrate into their research workflow”Post this The funding will accelerate … Continue reading Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth